These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 856462)

  • 21. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.
    Chan KK; Cohen JL; Gross JF; Himmelstein KJ; Bateman JR; Tsu-Lee Y; Marlis AS
    Cancer Treat Rep; 1978 Aug; 62(8):1161-71. PubMed ID: 688253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cysteine on the pharmacokinetics of intravenous adriamycin in rats with protein-calorie malnutrition.
    Kim YG; Cho MK; Kwon JW; Kim SG; Lee MG
    Res Commun Mol Pathol Pharmacol; 2000; 107(5-6):361-76. PubMed ID: 11589363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions between cyclophosphamide and adriamycin metabolism in rats.
    Dodion P; Riggs CE; Akman SR; Tamburini JM; Colvin OM; Bachur NR
    J Pharmacol Exp Ther; 1984 Apr; 229(1):51-7. PubMed ID: 6423814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of adriamycin and its fluorescent metabolites in human plasma by HPLC.
    Mahdadi R; Lhermitte M; Lafitte JJ
    Biomed Chromatogr; 1987 Feb; 2(1):38-40. PubMed ID: 3508093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daunorubicin metabolites in human urine.
    Takanashi S; Bachur NR
    J Pharmacol Exp Ther; 1975 Oct; 195(1):41-9. PubMed ID: 1181403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative studies on the pharmacokinetics between THP and adriamycin in the same patients].
    Nakajima O; Imamura Y; Matsumoto A; Koyama Y; Shomura T; Kawamura K; Murata S
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):261-70. PubMed ID: 3947106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.
    Creasey WA; McIntosh LS; Brescia T; Odujinrin O; Aspnes GT; Murray E; Marsh JC
    Cancer Res; 1976 Jan; 36(1):216-21. PubMed ID: 942583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA; Schmidt CG
    Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetics and metabolism of anthracyclines in man].
    Robert J
    Pathol Biol (Paris); 1987 Jan; 35(1):27-30. PubMed ID: 3550609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
    Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
    Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.
    Pendyala L; Cowens JW; Creaven PJ
    Cancer Treat Rep; 1982 Mar; 66(3):509-16. PubMed ID: 7060038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
    Cummings J; Milstead R; Cunningham D; Kaye S
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats.
    Lee HJ; Paik WH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):195-204. PubMed ID: 8832911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. II. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver.
    te Koppele JM; Dogterom P; Vermeulen NP; Meijer DK; van der Gen A; Mulder GJ
    J Pharmacol Exp Ther; 1986 Dec; 239(3):905-14. PubMed ID: 3795049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.
    Siebel C; Lanvers-Kaminsky C; Würthwein G; Hempel G; Boos J
    Sci Rep; 2020 Oct; 10(1):18562. PubMed ID: 33122763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenobarbital-induced alterations in vitamin D metabolism.
    Hahn TJ; Birge SJ; Scharp CR; Avioli LV
    J Clin Invest; 1972 Apr; 51(4):741-8. PubMed ID: 4335442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.
    Ozols RF; Willson JK; Weltz MD; Grotzinger KR; Myers CE; Young RC
    Cancer Res; 1980 Nov; 40(11):4109-12. PubMed ID: 7471054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
    Cummings J; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.